NFKB1 and COVID-19: When incorporated into the plasma membrane, they can affect the clumping of toll-like receptors associated with the prevention of signals that activate NF-κB, the production of other pro-inflammatory mediators, and the reduction in clinical complications in COVID-19 patients [51].